| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - Construction of new hybridoma lines against antigens potentially usable as targets for anti-tumour therapy. Elaboration of technology of preparation of recombinant fragments of monoclonal antibodies, mono- and multivalent. The increase of production of rStarting from the third year of the work of the Centre, to produce requested proteins for the needs of the Centre. Development of efficient purification methods of the produced recombinant antibodies. To propose structures, synthesis and the use of threProposal of structure, preparation and testing of biological effects of ligand (saccharide, peptide) dendrimeres and their application as immunodiagnostic and immunotherapeutic instruments. A practical output will be a polyfunctional bioconjugate containResearch of biotransformation path ways of anti-tumour drugs in relation to their effect. Development and synthesis of new anti-tumour drugs which are well tolerant by the organism (bioconjugates, targeted drugs). Verification of anti-tumour effects in v (en)
- Konstrukce nových hybridomových linií proti antigenům potenciálně využitelným, jako cíle pro protinádorovou léčbu.Vypracování technologie přípravy rekombinantních fragmentů monoklonálních protilátek, jedno vazebných i více vazebných. Zvýšení produkce reOd 3 roku projektu produkovat žádaný(é) proteiny pro potřeby Centra. Navržení efektivních metod purifikace produkovaných rekombinantních protilátek. Navržení struktury, syntéza a využití tří polymerních nosičových systémů pro konstrukci směrovaných léčNávrh struktury, příprava a testování biologických účinků ligandových (sacharidových, peptidových) dendrimerů a jejich aplikace jako imunodiagnostických a imunoterapeutických nástrojů. Praktickým výstupem bude vícefunkční biokonjugát obsahující dendrimerVýzkum biotransformačních drah protinádorových léčiv ve vztahu k jejich účinku. Vývoj a synthesa nových protinádorových léčiv dobře organismem tolerovaných (biokonjugáty, směrovaná léčiva). Ověřování protinádorových účinků in vivo s využitím experimentál
|
| Title
| - Center of targeted therapeutic drugs (en)
- Centrum cílených terapeutik
|
| skos:notation
| |
| http://linked.open...avai/cep/aktivita
| |
| http://linked.open...kovaStatniPodpora
| |
| http://linked.open...ep/celkoveNaklady
| |
| http://linked.open...datumDodatniDoRIV
| |
| http://linked.open...i/cep/druhSouteze
| |
| http://linked.open...ep/duvernostUdaju
| |
| http://linked.open.../cep/fazeProjektu
| |
| http://linked.open...ai/cep/hlavniObor
| |
| http://linked.open...hodnoceniProjektu
| |
| http://linked.open...vai/cep/kategorie
| |
| http://linked.open.../cep/klicovaSlova
| - monclonal and recombinant antibodies, radionuklides, targeted drugs (en)
|
| http://linked.open...ep/partnetrHlavni
| |
| http://linked.open...inujicichPrijemcu
| |
| http://linked.open...cep/pocetPrijemcu
| |
| http://linked.open...ocetSpoluPrijemcu
| |
| http://linked.open.../pocetVysledkuRIV
| |
| http://linked.open...enychVysledkuVRIV
| |
| http://linked.open...lneniVMinulemRoce
| |
| http://linked.open.../prideleniPodpory
| |
| http://linked.open...iciPoslednihoRoku
| |
| http://linked.open...atUdajeProjZameru
| |
| http://linked.open.../vavai/cep/soutez
| |
| http://linked.open...usZobrazovaneFaze
| |
| http://linked.open...ai/cep/typPojektu
| |
| http://linked.open...ep/ukonceniReseni
| |
| http://linked.open.../cep/vedlejsiObor
| |
| http://linked.open...ep/zahajeniReseni
| |
| http://linked.open...jektu+dodavatelem
| - Projekt splnil hlavní cíle. Spoluprací vědeckých a navazujících aplikačních pracovišť byly získány v oblasti produkce cílených terapeutik výsledky s adekvátní vědeckou hodnotou a s aplikačním potenciálem. (cs)
- The major aims of the project were achieved. Results of corresponding scientific quality with the potential of applications were produced in the field of targeted therapeutics in collaboration of research institutions and industrial partners. (en)
|
| http://linked.open...tniCyklusProjektu
| |
| http://linked.open.../cep/klicoveSlovo
| - radionuklides
- monclonal and recombinant antibodies
|
| is http://linked.open...vavai/riv/projekt
of | - Phosphoenolpyruvate carboxylase, NADP-malic enzyme, and pyruvate, phosphate dikinase are involved in the acclimation of Nicotiana tabacum L. to drought stress
- TCR alpha-beta - biotin
- Technologie značení komonomeru HPMA-co-aminopropyl-HYNIC, určeného k diagnostice tumorů izotopem 99mTc.
- Labeling of HPMA-co-Ma-aminopropyl-co-MA-AH-DOX conjugate with 99mTc for combined tumor diagnostics and therapy.
- Technologie přípravy radionuklidu 177Lu v jaderném reaktoru
- Technologie značení lyofilizovaných konjugátů monklonálních protilátek s bifunkčním chelátorem OSSU-DOTA radionuklidem 177-Lu
- Technologie značení lyofilizovaných konjugátů protilátky s bifunkčním chelátorem isothiokyanátobenzyl-DTPA radionuklidem 177Lu
- Technologie značení biotinu radionuklidy
- Technologie značení MCN 5668 radionuklidem 11C
- Technologie značení konjugátu komonomeru radionuklidy 177Lu a 67Ga
- Technologie značení lyofilizovaných konjugátů MAb-HYNIC
- Isolation of cytoplasmic NADPH-dependent phenol hydroxylase and catechol-1,2-dioxygenase from Candida tropicalis yeast
- Isolation and partial characterization of catechol 1,2-dioxygenase of phenol degrading yeast Candida tropicalis
- Humoral response against Mycobacterium bovis Hsp65 derived fragments in children and young people with various disorders
- A one-electron oxidation of carcinogenic nonaminoazo dye Sudan I by horseradish peroxidase
- HPMA copolymer conjugates for dual therapy
- Polymer drug carriers for passive and active tumour targeting
- Biodegradable high-molecular-weight multiblock polymers based on poly(ethylene glycol) for drug delivery
- Carrier-based radiochemotherapy
- Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
- Polymerní „drug delivery“ systémy pro radiofarmaka
- Polymerní terapeutika u nás a ve světě
- Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers
- HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity
- Thermoresponsive hydrolytically degradable polymer micelles intended for radionuclide delivery
- Thermoresponsive micelles for radionuclide delivery
- New coupling strategy for radionuclide labeling of synthetic polymers
- Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy
- Stimuli responsive polymeric micelles for drug delivery purposes
- HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release
- Polyoxazoline thermoresponsive micelles as radionuclide delivery systems
- Long-circulating and passively tumor-targeted polymer-drug conjugates improve the efficacy and reduce the toxicity of radiochemotherapy
- Micellar and antibody-targeted polymer therapeutics
- Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through and amide or hydrazone bond
- HPMA – Anticancer Drug Conjugates
- Transient expression of human papillomavirus type 16 virus-like particles in tobacco and tomato using a tobacco rattle virus expression vector
- Down-regulation of protein-tyrosine phosphatases activates an immune receptor in the absence of its translocation into lipid rafts
- Identification of Carbonic Anhydrase I Immunodominant Epitopes Recognized by Specific Autoantibodies Which Indicate an Improved Prognosis in Patients with Malignancy after Autologous Stem Cell Transplantation
- Consumption of Brussels sprouts protects peripheral human lymphocytes against 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhlP) and oxidative DNA-damage: results of a controlled human intervention trial
- Využití rostlin k produkci protilátek
- Rapid repair of DNA double strand breaks in Arabidopsis thaliana is dependent on proteins involved in chromosome structure maintenance
- Regulation of phosphoenolpyruvate carboxylase in PVYNTN-infected tobacco plants
- DNA ligase 1 deficient plants display severe growth defects and delayed repair of both DNA single and double strand breaks
- The regulation and catalytic mechanism of the NADP-malic enzyme from tobacco leaves
- Effect of Potato Virus Y on the NADP-Malic Enzyme from Nicotiana tabacum L.: mRNA, Expressed Protein and Activity
- Characterization of phosphoenolpyruvate carboxylase from mature maize seeds: Properties of phosphorylated and dephosphorylated forms
- Efficient biolistic transformation of the moss Physcomitrella patens
- Oxidation of the carcinogenic non-aminoazo dye 1-phenylazo-2-hydroxynaphthalene (Sudan I) by cytochromes P450 and peroxidases: a comparative study
- Analysis of benzo[a]pyrene metabolites formed by rat hepatic microsomes using high pressure liquid chromatography: optimization of the method
- Genotoxic mechanisms for the carcinogenicity of the environmental pollutants and carcinogens o-anisidine and 2-nitroanisole follow from adducts generated by their metabolite N-(2-methoxyphenyl)-hydroxylamine with deoxyguanosine in DNA
- Oxidation of 3-aminobenzanthrone, a human metabolite of carcinogenic environmental pollutant 3-nitrobenzanthrone, by cytochromes P450 ? similarity between human and rat enzymes
- Rat cytochromes P450 oxidize 2-nitrophenol, a human metabolite of carcinogenic 2-nitroanisole
- Preparation of apo-cytochrome b5 utilizing heme transfer to apo-myoglobin
- 3-Aminobenzanthrone, a human metabolite of the carcinogenic environmental pollutant 3-nitrobenzanthrone, induces biotransformation enzymes in rat kidney and lung
- Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells
- The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells
- Enzymy Hatchova-Slackova cyklu v C3 rostlinách
- Cytochrome P450 3A activities and their modulation by alfa-naphthoflavone in vitro are dictated by the efficiencies of model experimental systems
- Identification of human enzymes oxidizing a human metabolite of carcinogenic 2-nitroanisole, 2-nitrophenol. Evidence for its oxidative detoxification by human cytochromes P450.
- Mechanisms of the different DNA adduct forming potentials of the urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)